Abstract | BACKGROUND AND OBJECTIVES:
Chancroid is endemic in sub-Saharan Africa and enhances the sexual transmission of the human immunodeficiency virus Type 1 (HIV-1). Azithromycin is an orally absorbed macrolide antibiotic that is active against Haemophilus ducreyi, the causative agent of chancroid, and has pharmacokinetic properties that are suitable for single dosing. STUDY DESIGN: In a randomized single-blinded study of 127 men presenting to a referral STD clinic with culture proven chancroid, we compared the efficacy of azithromycin, administered as a single 1 g dose, with erythromycin 500 mg given 4 times daily for 7 days. RESULTS: Cure rates were 89% (73 of 82) in the azithromycin group and 91% (41 of 45) in the erythromycin group. A failure to respond to treatment was associated with HIV-1 seropositivity and a lack of circumcision. Both regimens were well tolerated. CONCLUSIONS:
|
Authors | M W Tyndall, E Agoki, F A Plummer, W Malisa, J O Ndinya-Achola, A R Ronald |
Journal | Sexually transmitted diseases
(Sex Transm Dis)
1994 Jul-Aug
Vol. 21
Issue 4
Pg. 231-4
ISSN: 0148-5717 [Print] United States |
PMID | 7974076
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Erythromycin
- Azithromycin
|
Topics |
- AIDS-Related Opportunistic Infections
(drug therapy, epidemiology, microbiology)
- Administration, Oral
- Adult
- Azithromycin
(administration & dosage)
- Chancroid
(drug therapy, epidemiology, microbiology)
- Circumcision, Male
- Erythromycin
(administration & dosage)
- HIV-1
- Humans
- Male
- Referral and Consultation
- Risk Factors
- Single-Blind Method
- Treatment Failure
|